×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Concern is that established players like Sandoz, Teva are moving out: Lupin
USFDA warning: Lupin sees marginal impact on earnings; resolution to take 12-15 mths
Expect acquisitions to boost growth; several products lined up for next year: Lupin
Will unleash significant portion of product pipeline by 2020: Lupin
Lupin's growth in US to stay muted next year
Can grow at 18%; expect margins at 30% going ahead: Lupin
Not positive on Lupin's US business: Surajit Pal
Regulatory risks waning in pharma sector: IIFL
Lupin to see approvals after US FDA gives clean chit: Macquarie
In a relief to Lupin, US FDA closes 9 inspections made last year
Aspire to hit $5 bn in sales soon; focus on specialty biz: Lupin
Booster dose: Lupin unit gets US FDA clearance
Indian pharma cos need to step-up safeguards at plants: Handa
Cautious on Lupin as no clarity yet on USFDA action: Surajit Pal
Pharma cos capable of resolving FDA concern in 12-15 months:IIFL
Expect 26-28% op margin growth; eye more acquisitions: Lupin
US FDA approvals to see uptick from 2016: Lupin
Gavis arm Wintac not part of acquisition, says Lupin CFO
No material launch, price erosion impacted earnings: Lupin
Expect FY16 US generic launch for Nexium: Lupin
Always believe growth will come from acquisitions: Lupin
HDFC Bk can raise up to Rs 10k cr, Lupin to hike FDI limit
Yen depreciation to impact Japan business revenue: Lupin
Sun's margins may reduce to 30-32% post merger: Surajit Pal
Competition, seasonality led to weak Q2 results: Lupin
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio